Johannes Ottl

1 Patent

• US122091442025

  Cyclic Peptides as Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) Inhibitors for the Treatment of Metabolic Disorders

  Novartis AG

  0 cites